REFERENCES
1.Elvira D’Andrea, Spencer P. Hey, Cherie L. Ramirez, et al. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes:A Systematic Review and Meta-analysis.JAMA Network Open . 2019,2(4):e192224.
2. Paul M.Lavigne, Richard H.Karas. The Current State of Niacin in Cardiovascular Disease Prevention: A Systematic Review and Meta-Regression. J Am Coll Cardiol .2013,61(4): 440-446.
3. R. Fogari, G. Marasi, A. Vanasia, A. Zoppi, P. Lusardi, et al. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia. Int J Clin Pharmacol Ther .1997,35(2):61-64.
4.Miroslav Zeman, Marek Vecka, František Perlík, Barbora Staňková, Robert Hromádka, Eva Tvrzická, Jakub Širc, Jakub Hrib, Aleš Žák. Pleiotropic effects of niacin: Current possibilities for its clinical use. Acta Pharmaceutica , 2016,66(4):449-469.
5.G Crepaldi , P Avogaro, G C Descovich, et al. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.Atherosclerosis , 1988, 70(1-2):115-121.
6.Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep, 2 000;2:36 – 46.
7.Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? . J Am Coll Cardiol. 2007;100:S53– 61.
8. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy .N Engl J Med 2011;365:2255-2267.
9.Alsheikh-Ali AA, Karas RH. The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am J Gastroenterol, 2008,101:9B–13B.
10.Chalasani NP, Hayashi PH, Bonkovsky HL, et al. Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.Am J Gastroenterol ,2014 ,109 (7) :950-966.
11.Don C. Rockey, Leonard B. Seeff, James Rochon, et al. Fontana, and Paul H. Hayashi, for the US Drug-Induced Liver Injury Network. Causality Assessment in Drug-Induced Liver Injury Using a Structured Expert Opinion Process: Comparison to the Roussel-Uclaf Causality Assessment Method. Hepatology . 2010,51(6): 2117–2126
12. Adrian Reuben, David G Koch, William M Lee, Acute Liver Failure Study Group Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology , 2010;52(6):2065-2076
13. Michael F Vaezi, John E Pandolfino, Marcelo F Vela. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol , 2013;108(8):1238-1249.
14. P Harrison , J Wendon, R Williams. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. Hepatology ,1996 ,23(5):1067-1072.
15.The Study of Drug Induced Liver Disease of Chinese Medical Association. Diagnosis and treatment guideline on drug-induced liver injury. Chinese Journal of Hepatology ,2015,23(11):810-820.
16.Y.f. Wang , Z.h. Wang , M.q. Gao ,et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: A phase II trial. Liver International . 2019,39(11):2102-2111.
17.Xie C, Li X, Wu J, et al. Anti‐inflammatory activity of magnesium isoglycyrrhizinate through inhibition of phospholipase A2/arachidonic acid pathway.Inflammation . 2015;38(4):1639-1648.
18.Huang X, Qin J, Lu S. Magnesium isoglycyrrhizinate protects hepatic L02 cells from ischemia/reperfusion induced injury. Int J Clin Exp Pathol. 2014; 7(8): 4755– 4764.